Patient Research
Sign in
All studies
RecruitingPHASE1, PHASE2INTERVENTIONAL

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

At a glance

Status
Recruiting
Phase
PHASE1, PHASE2
Sponsor
Tangram Therapeutics Plc
Enrolment target
99
Start
03 Mar 2026
Estimated completion
01 Jun 2028
Healthy ParticipantsMASH - Metabolic Dysfunction-Associated Steatohepatitis

What is this study about?

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Who may be eligible?

Age 18 Years to 70 Years · Sex: ALL

Locations (1)

  • Richmond Pharmacology
    London, United Kingdom· Recruiting

How to find out more

Sponsor Clinical Trials Office

clinicaltrials@tangramtx.com +44 20 4558 3826 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Study of TGM-312-SC01 in Healthy Participants and Adults Wit…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.